Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Mohammed A Elghiriani, Salah S Naga, Ibtessam A Hameed, Iman E Elgohary, Amal R Mansour
INTRODUCTION: Lupus is a diverse autoimmune disease with autoantibody formation. Lupus nephritis carries a grave prognosis. Complement involvement, namely, C1q deficiency, is linked to activity and renal involvement and could help in their assessment. LN therapies include plasma exchange, immune adsorption, and probably hemodiafiltration with online endogenous reinfusion (HFR), together with traditional immunosuppressive therapies. AIM: The aim of this study was to evaluate the role of HFR in improving signs and symptoms of systemic lupus erythematosus (SLE) activity and laboratory parameters in cases not responding to traditional immunosuppressive therapy...
2024: Front Nephrol
#22
REVIEW
Eleni Papachristodoulou, Vasileios C Kyttaris
Systemic Lupus Erythematosus (SLE) and lupus nephritis treatment is still based on non-specific immune suppression despite the first biological therapy for the disease having been approved more than a decade ago. Intense basic and translational research has uncovered a multitude of pathways that are actively being evaluated as treatment targets in SLE and lupus nephritis, with two new medications receiving FDA approval in the last 3 years. Herein we provide an overview of targeted therapies for SLE including medications targeting the B lymphocyte compartment, intracellular signaling, co-stimulation, and finally the interferons and other cytokines...
April 4, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#23
JOURNAL ARTICLE
Antonis Fanouriakis, Myrto Kostopoulou, George Bertsias, Dimitrios T Boumpas
No abstract text is available yet for this article.
April 5, 2024: Annals of the Rheumatic Diseases
#24
JOURNAL ARTICLE
Yasser Bawazir
Systemic lupus erythematosus mainly affects young women, and approximately half of systemic lupus erythematosus patients develop lupus nephritis (LN). However, data on the types and remission rates of LN in Saudi Arabia are limited. Therefore, we aimed to highlight the LN remission rates in our population. A retrospective record review was conducted between January 2007 and December 2020 in a tertiary center in the western region of Saudi Arabia to determine the remission rates among patients with biopsy-proven LN who met the EULAR\ACR 2019 classification criteria...
April 5, 2024: Medicine (Baltimore)
#25
Edgar Dehesa-Lopez, Sergio Saul Irizar-Santana, Miguel Angel Valdez-Cruz, Sarahy Sosa-Guerrero, Fatima Lopez-Moreno
Patients with end-stage renal disease (ESRD) who undergo kidney transplantation are at an increased risk of developing surgical and/or medical complications. Posterior reversible encephalopathy syndrome (PRES) is a rare complication that occurs in 0.34% of kidney transplant patients. It is characterized by a combination of neurological manifestations, risk factors, and characteristic radiological findings in neuroimaging studies. The development of PRES has been associated with various medical conditions and factors, including hypertension, the use of cytotoxic and immunosuppressive drugs, acute or chronic kidney disease, pre-eclampsia/eclampsia, autoimmune diseases, and solid organ and bone marrow transplantation...
March 2024: Curēus
#26
JOURNAL ARTICLE
Diangeng Li, Yanchun Li, Kaiyi Zhu, Yuqing Yuan, Zheng He, Qianmei Sun, Meiling Jin
BACKGROUND: Lupus nephritis (LN) is the most common and severe clinical manifestation of systemic lupus erythematosus (SLE). N6-methyladenosine (m6A) is a reversible RNA modification and has been implicated in various biological processes. However, the roles of m6A regulators in LN are not fully demonstrated. METHODS: We downloaded the kidney tissue transcriptome dataset of LN patients and normal controls from the GEO database and extracted the expression levels of m6A regulators...
April 3, 2024: BMC Nephrology
#27
REVIEW
Yi Zhou, Zhangxue Hu
The interleukin (IL)-17 axis is involved in many inflammatory and autoimmune diseases. Secukinumab, an IL-17 inhibitor, has been approved for psoriasis treatment. There are accumulating cases of lupus erythematosus induced by IL-17 inhibition. Lupus nephritis after IL-17 inhibition has not been reported. We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low...
May 2024: Lupus
#28
JOURNAL ARTICLE
Sofía Ornella, Lucila García, Máximo Cosentino, Marcelo F Taylor, Martín Ciappa, Mercedes A García
INTRODUCTION: Although RT has improved the survival of the population with ESRD due to all causes, renal outcomes in SLE are controversial. The objective of this study is to describe the characteristics and evolution of the patients and the kidney transplant in LN, and compare it with patients transplanted for other causes. MATERIALS AND METHODS: Retrospective, observational, analytical, single-center study in which records of patients undergoing nephrotransplantation for LN were analyzed...
April 3, 2024: Lupus
#29
JOURNAL ARTICLE
Bernadete L Liphaus, Simone C Silva, Patrícia Palmeira, Clovis A Silva, Claudia Goldenstein-Schainberg, Magda Carneiro-Sampaio
BACKGROUND: Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer (NK) cells have also been implicated. This study assessed apoptosis-related protein expressions in NK cells of patients with juvenile-onset systemic lupus erythematosus (jSLE) and relations to disease activity parameters, nephritis, and neuropsychiatric involvement...
2024: Frontiers in Immunology
#30
EDITORIAL
Gabriel Nicolas Contreras Martin
Lupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2 .
April 1, 2024: Journal of Rheumatology
#31
JOURNAL ARTICLE
Jordan E Roberts, Anna Faino, Mersine A Bryan, Jonathan D Cogen, Esi M Morgan
OBJECTIVE: We aimed to determine the frequency and types of infections in hospitalized children with childhood-onset systemic lupus erythematosus (cSLE), and to identify risk factors for intensive care unit (ICU) admission and mortality. METHODS: We conducted a retrospective study of youth 2-21 years of age with ICD codes for SLE during admission to a hospital participating in the Pediatric Health Information System, a database of United States children's hospitals, from 2009-2021...
April 1, 2024: Journal of Rheumatology
#32
Rabia Deniz, Gülşah Hacımurtazaoğlu-Demir, Bilgin Karaalioğlu, Duygu Sevinç Özgür, Gamze Akkuzu, Fatih Yıldırım, Cemal Bes
The triad of ascites, pleural effusion, and elevated cancer antigen-125 (CA-125) levels in the absence of ovarian malignancy in systemic lupus erythematosus patients is specifically named pseudo-pseudo Meigs' syndrome (PPMS) or Tjalma syndrome. In this case we reported a 33 years female patient with pleural effusion lasting for 3 years and new onset progressive massive ascites and increased level of CA-125. After she was evaluated for an underlying benign and malign ovarian tumor or any other malignancies, serologic tests were requested with respect to progressive renal dysfunction, proteinuria, lymphopenia, anemia, and effusion...
April 1, 2024: Journal of rheumatic diseases
#33
Ralina Karagenova, Ziga Vodusek, Rebecca Krimins, Adam Krieger, Homa Timlin
Systemic lupus erythematosus (SLE) is a complex heterogeneous disease with multiple clinical manifestations. Recently, two medications, anifrolumab and voclosporin, have been approved for the treatment of adults with SLE and lupus nephritis (LN), respectively. We present the case of an elderly woman with LN and refractory discoid lupus erythematosus (DLE), who was treated successfully with a combination of voclosporin and anifrolumab without major infections.
March 2024: Curēus
#34
JOURNAL ARTICLE
Filipa Farinha, Anisur Rahman
No abstract text is available yet for this article.
2024: ARP Rheumatol
#35
JOURNAL ARTICLE
Tongtong Yi, Wei Zhang, Ying Hua, Xingpan Xin, Zhenyu Wu, Ying Li, Chengping Wen, Yongsheng Fan, Jinjun Ji, Li Xu
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by complex clinical symptoms and multi-organ damage. One of the most prevalent complications of SLE is lupus nephritis (LN). Rutin, a natural flavonoid compound found in various plants used in traditional Chinese medicine, has shown promising anti-inflammatory, antioxidant, and renal protective effects. In our study, we treated MRL/lpr mice, a model known for spontaneously developing LN, with Rutin. Our findings reveal that Rutin markedly reduced serum cytokine and autoantibody levels and decreased inflammatory cell infiltration in renal tissues, thereby ameliorating kidney pathology...
March 28, 2024: Chemico-biological Interactions
#36
REVIEW
Maurizio Bruschi, Andrea Angeletti, Marco Prunotto, Pier Luigi Meroni, Gian Marco Ghiggeri, Gabriella Moroni, Renato Alberto Sinico, Franco Franceschini, Micaela Fredi, Augusto Vaglio, Andrea Cavalli, Leonardo Scapozza, Jigar J Patel, John C Tan, Ken C Lo, Lorenzo Cavagna, Andrea Petretto, Federico Pratesi, Paola Migliorini, Francesco Locatelli, Giulia Pazzola, Giampaola Pesce, Domenico Giannese, Angelo Manfredi, Giuseppe A Ramirez, Pasquale Esposito, Giuseppe Murdaca, Simone Negrini, Federica Bui, Barbara Trezzi, Giacomo Emmi, Ilaria Cavazzana, Valentina Binda, Paride Fenaroli, Isabella Pisan, Carlomaurizio Montecucco, Domenico Santoro, Francesco Scolari, Federica Mescia, Stefano Volpi, Marta Mosca, Angela Tincani, Angelo Ravelli, Corrado Murtas, Giovanni Candiano, Gianluca Caridi, Edoardo La Porta, Enrico Verrina
Deposition of autoantibodies in glomeruli is a key factor in the development of lupus nephritis (LN). For a long time, anti-dsDNA and anti-C1q antibodies were thought to be the main cause of the kidney damage. However, recent studies have shown that the list of autoantibidies that have renal tropism and deposit in the kidney in LN is increasing and the link between anti-dsDNA and renal pathology is weak due to potential confounders. Aspecific bindings of dsDNA with cationic antibodies and of anti-dsDNA with several renal antigens such as actinin, laminin, entactin, and annexinA2 raised doubts about the specific target of these antibodies in the kidney...
March 27, 2024: Autoimmunity Reviews
#37
JOURNAL ARTICLE
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Belimumab was approved for active lupus nephritis (LN) in adults in the European Union and patients ≥ 5 years of age in the USA based on a Phase 3, double-blind, placebo-controlled, 104-week study. The study evaluated the efficacy of belimumab plus background standard therapy in adults with active LN using an intravenous (IV) dose of 10 mg/kg. A longitudinal analysis of Primary Efficacy Renal Response (PERR) and Complete Renal Response (CRR) was performed to assess whether patients with high proteinuria at the start of belimumab treatment would benefit from a higher dose...
March 29, 2024: Journal of Pharmacokinetics and Pharmacodynamics
#38
JOURNAL ARTICLE
Yevgeniya Gartshteyn, Laura Geraldino-Pardilla, Leila Khalili, Shoiab Bukhari, Shalom Lerrer, Robert J Winchester, Anca D Askanase, Adam Mor
INTRODUCTION: T follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein (SAP) regulates TFH and TPH function by binding to the co-stimulatory signaling lymphocyte activation molecule family (SLAMF) receptors that mediate T cell - B cell interactions. SAP and SLAMF are critical for TPH-dependent B cell maturation into autoantibody-producing plasma cells that characterize SLE pathogenesis...
2024: Frontiers in Immunology
#39
JOURNAL ARTICLE
Jarukit Mongkolchaiarunya, Antika Wongthanee, Nuntana Kasitanon, Worawit Louthrenoo
BACKGROUND: Studies have found that late-onset systemic lupus erythematosus (SLE) patients (age at diagnosis ≥ 50 years) had less severe disease and milder clinical course, but with higher organ damage and mortality rate than early-onset ones (age at diagnosis < 50 years). Unfortunately, direct comparison of renal manifestations and treatment outcomes between late- and early-onset SLE patients has been determined rarely. This study aimed to compare lupus nephritis (LN) manifestations, treatment, and outcomes between late- and early-onset in SLE patients...
March 2024: Journal of Clinical Medicine Research
#40
JOURNAL ARTICLE
Joanna Kosałka-Węgiel, Radosław Dziedzic, Andżelika Siwiec-Koźlik, Magdalena Spałkowska, Mamert Milewski, Joanna Żuk-Kuwik, Lech Zaręba, Stanisława Bazan-Socha, Mariusz Korkosz
BACKGROUND: Lupus nephritis (LN) manifests systemic lupus erythematosus (SLE) and is characterized by various clinical and laboratory features. This study aimed to comprehensively evaluate the characteristics of LN patients according to the time of LN diagnosis: early-onset (LN diagnosed within one year from SLE diagnosis) vs. delayed-onset (LN diagnosed more than one year after SLE diagnosis). METHODS: We conducted a retrospective analysis of medical records from all SLE patients treated at the University Hospital in Kraków, Poland, from 2012 to 2022...
March 28, 2024: Rheumatology International
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
